Medivation, Inc. (MDVN) on Monday announced top-line results of a Phase 2 study showing that its investigational drug Dimebon significantly improved cognitive function in patients with mild-to-moderate Huntington's disease.
The primary endpoint of the trial was safety and tolerability. The secondary endpoint was efficacy, as measured by the MMSE, the UHDRS and the Alzheimer's Disease Assessment Scale-cognitive subscale.
Results showed that Dimebon was very well tolerated in this trial. The overall incidence of adverse events was lower in the Dimebon group than in the placebo group, an unusual finding in a clinical study of any drug.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.